Janus Henderson Group PLC Reduces Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Janus Henderson Group PLC lessened its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 9.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,834 shares of the medical instruments supplier's stock after selling 5,268 shares during the period. Janus Henderson Group PLC owned 0.23% of LeMaitre Vascular worth $4,722,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Driehaus Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 52.2% in the second quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier's stock valued at $21,740,000 after purchasing an additional 90,573 shares during the period. F M Investments LLC purchased a new position in LeMaitre Vascular during the 2nd quarter worth $7,443,000. Nicholas Investment Partners LP acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter worth $3,900,000. Conestoga Capital Advisors LLC increased its stake in shares of LeMaitre Vascular by 1.9% during the third quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier's stock worth $183,769,000 after acquiring an additional 36,850 shares during the period. Finally, Rice Hall James & Associates LLC lifted its position in LeMaitre Vascular by 15.7% in the third quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier's stock valued at $24,273,000 after purchasing an additional 35,383 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the business's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company's stock, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.79% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LMAT. Barrington Research boosted their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Oppenheimer reiterated an "outperform" rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a "neutral" rating and a $96.00 target price on the stock. StockNews.com upgraded shares of LeMaitre Vascular from a "hold" rating to a "buy" rating in a report on Thursday, December 5th. Finally, JMP Securities boosted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 20th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, LeMaitre Vascular currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.57.

LeMaitre Vascular Stock Performance

LMAT stock traded up $1.60 on Wednesday, reaching $101.00. The company had a trading volume of 148,299 shares, compared to its average volume of 124,208. LeMaitre Vascular, Inc. has a 1 year low of $52.72 and a 1 year high of $109.58. The company's fifty day moving average is $97.28 and its 200 day moving average is $89.25. The company has a market cap of $2.27 billion, a P/E ratio of 55.19, a PEG ratio of 2.48 and a beta of 0.93.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to analyst estimates of $53.50 million. During the same quarter last year, the company earned $0.33 earnings per share. The business's revenue for the quarter was up 15.6% compared to the same quarter last year. On average, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were issued a $0.16 dividend. The ex-dividend date of this dividend was Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.63%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 34.97%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.